Table 3.
Various vaccines involved to provide immunity against SARS-CoV-2
| Vaccine name | Manufacturer | Country | Mechanism | Efficacy |
|---|---|---|---|---|
| BNT162b2 and BNT162b1 | Pfizer-BioNTech | USA | mRNA | 94% |
| MRNA-1273 | Moderna | USA | mRNA | 94% |
| Ad26.COV2.S | Johnson and Johnson | USA | Viral vector | 66% |
| AZD1222 | AstraZeneca and Oxford University | USA and England | Viral vector | 70% |
| NVX-CoV2373 | Novavax | USA | Recombinant nanoparticle | 89.3% |
| BBIBP-CoV | Sinopharm | China | Inactivated virus | 78% |
| CoronaVac | Sinovac | China | Inactivated virus | 50–84% |
| HBO2 | Beijing Institute of Biological Products Co., Ltd | China | Inactivated virus | 78.1% |
| Gam-COVID-Vac (Sputnik V) | Gamaleya | Russia | Viral vector | 91.6% |